DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Boston Convention and Exhibition Center

2018年6月24日 (日) 午前 8:30 - 2018年6月24日 (日) 午後 12:00

415 Summer Street, , Boston, MA 02210 , USA

#27: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment

Instructors

Jack M. Mycka

Jack M. Mycka

Global President and CEO, Medical Marketing Economics LLC (MME), United States

As MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations.

Richard J. Willke, PhD

Richard J. Willke, PhD

Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), United States

Dick became ISPOR’s first Chief Science Officer in 2016, where he develops, leads, and supports strategic initiatives related to research, scientific, and content priorities. Prior to ISPOR he worked for 25 years at Pfizer and its legacy companies, where he retired as a vice president in the HEOR group. He received a PhD in economics from Johns Hopkins, taught economics at Ohio State, and was senior economist at the American Medical Association. He has been a co-editor for Value in Health, on AHRQ, NIH, and PCORI study sections, and chaired the PhRMA Health Outcomes Committee.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。